LabCorp

What LabCorp does

Labcorp (Laboratory Corporation of America Holdings; NYSE: LH) is a U.S.-headquartered, publicly traded life sciences company operating two principal segments: Diagnostics and Biopharma Laboratory Services. The Diagnostics business provides clinical laboratory testing across 6,500+ assays to physicians, nearly 4,000 hospitals and health systems, 700+ health plans, employers, and individual consumers, leveraging a network of 2,200+ patient service centers that reach 95% of the U.S. population and 90% of covered lives in-network, supported by 1,200+ PhDs/MDs and 750+ million tests performed in 2025. Consumer access is delivered through Labcorp OnDemand, the Walgreens retail partnership, GetLabs at-home collection, and the AI-powered MyLabcorp mobile app.

The Biopharma Laboratory Services segment supports drug development from nonclinical research through clinical trial central lab services, contributing to over 85% of new FDA-approved drugs and carrying an $8.6B trailing 12-month backlog. Its proprietary technology stack spans molecular diagnostics, genomics, and pathology with AI-enabled layers including the Diagnostic Assistant test finder, the AWS/Datavant-powered real-world data platform, MVX biomarker scoring, Plasma Detect Genome MRD liquid biopsy, and expanded partnerships with PathAI (digital pathology) and Illumina (comprehensive genomic profiling).

The business model combines high-volume, recurring clinical testing revenue from hospital and physician clients, payor contracts under both in-network fee schedules and Medicare reimbursement (e.g., NASHnext at ~$252/test), specialty genetic and esoteric testing with higher per-test economics (ColoSense, Elecsys pTau-181, DPYD genotyping, Vectra), direct-to-consumer pay-as-you-go testing, and enterprise contracts with biopharma sponsors. Revenue is diversified across segments, with FY2026 guided at $14.65-$14.80B (5.0%-6.1% growth) and Q1 2026 reported at $3.54B (+5.8% YoY).

Name

LabCorp

Legal name

Laboratory Corporation of America Holdings

Website

https://labcorp.com

Company type

Public

Founded year

1976

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Labcorp (NYSE: LH) is a U.S. clinical diagnostics and drug development company serving physicians, hospitals, health plans, biopharma sponsors, and consumers through 2,200+ patient service centers, specialty genetic and esoteric assays, central lab services, and AI-enabled data platforms.

Ownership category

akta.pro rank

Product category

Clinical Laboratory Diagnostics

NAICS

Medical Laboratories (621511), In-Vitro Diagnostic Substance Manufacturing (325413)

SIC

Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Clinical Chemistry & Immunoassay Laboratories (HLAFAMAB)

akta.pro secondary industries

Reference & Esoteric Testing Laboratories (HLAFAMAJ), Clinical Research & Trial Central Laboratories (HLAFAMAL), Central Laboratory & Clinical Trial Testing CROs (HLAGAAAE), Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays) (HLAAAMAC)

Keywords

• Clinical laboratory diagnostics
• Drug development services
• Biopharmaceutical central laboratory
• Molecular and genomic testing
• Anatomic pathology services

Headquarters

HQ city

Burlington

HQ country

United States

HQ region

North America

Offices7 records

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Personnel, Operations, Supply Chain, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Diagnostic Testing Services: Provides clinical laboratory testing services to patients and healthcare providers through a network of 2,200+ patient service centers. Revenue generated from test processing, specimen collection, and analysis across routine and specialty diagnostics.
2. Biopharma Laboratory Services / Drug Development: Supports pharmaceutical and biotech companies with nonclinical development, central lab services, and clinical trial support. Services span from discovery through regulatory submission, supporting over 85% of new FDA-approved drugs.
3. Employer Wellness and Drug Testing: Provides workplace drug testing, biometric screenings, health coaching, and wellness programs to employers. Impacts 9M+ lives annually.
4. Managed Care and Health Plan Services: Partners with health plans and payors providing laboratory services, gaps in care solutions, and data analytics to improve patient outcomes and reduce costs.

Pricing tiers

Go-to-market motion4 records

Distribution channels8 records

Marketing channels8 records

Core offering

LabCorp provides clinical laboratory diagnostics and drug development services through a U.S. network of 2,200+ patient service centers and global central laboratories. Offerings include routine and specialty clinical testing, anatomic pathology, genomic and molecular diagnostics, women's health, companion diagnostics, early development/nonclinical services, and central laboratory services for clinical trials. The company also sells testing directly to consumers via Labcorp OnDemand.

Product overview

LabCorp operates as a diversified life sciences company offering a unified platform of diagnostic testing and drug development services. The core Diagnostics segment provides routine and esoteric laboratory testing through 2,200+ patient service centers, while the Central Laboratory Services and Nonclinical Development divisions support clinical trials and preclinical research for pharmaceutical clients. The Real World Data Solutions platform, developed with AWS and Datavant, leverages AI and longitudinal lab data to accelerate drug development. Consumer-facing products include Labcorp OnDemand for self-ordered tests and MyLabcorp, an AI-powered app for result interpretation. The portfolio incorporates acquired brands including Invitae genetic testing, Ovia Health women's health, and PGDx liquid biopsy testing. Provider tools span Labcorp Link for EHR integration, specialty portals (OmniSeq, PGDx), and AI-powered diagnostic assistant. Employer Services delivers workplace wellness and drug testing solutions, while Companion Diagnostics identifies patients eligible for targeted therapies.

Differentiator

Problem solved

Functional benefit

Brands

• MyLabcorp: AI-powered mobile app that helps consumers understand their lab results, tracks health trends over time, and allows users to manage appointments and billing.
• Labcorp Link
• Labcorp OnDemand
• Labcorp Point of Care (formerly MEDTOX Diagnostics)
• OmniSeq
• PGDx
• PATHways
• Labcorp Accelerate
• Labcorp Plasma Detect Genome MRD
• Labcorp Diagnostic Assistant
• Invitae
• Ovia Health
• Labcorp Corporate Solutions
• Wellness Connect Plus
• ColoSense
• Elecsys pTau-181

Products and services

• Clinical Laboratory Diagnostics Services

Quantifiable outcome

• Over 85% of new drugs and therapeutic products approved by the U.S. FDA were supported by Labcorp
• +4 more outcomes

Named customers11 records

Segments6 records

Ideal customer profiles6 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration11 records

AI capability11 records

Feature8 records

Partnerships

20 partnerships are on record, tiered core, flagship and minor.

• GENFITcoreOEM/ Whitelabel/ Licensing Partner · 2 July 2026Labcorp developed and commercializes NASHnext, a non-invasive blood-based diagnostic test for identifying patients with at-risk MASH, using GENFIT's proprietary NIS4 technology. Medicare coverage secured at approximately $252 per test.
• Optum AIcoreTechnology or Integration · 30 June 2026Strategic collaboration announced as part of Labcorp's Q1 2026 strategic initiatives to expand AI-powered healthcare solutions.
• GeneoscopyflagshipStrategic or Co-development Partner · 22 June 2026Labcorp announced nationwide availability of ColoSense, the first FDA-approved RNA-based at-home colorectal cancer screening test, through a commercial collaboration with Geneoscopy. The test demonstrated 93% sensitivity for colorectal cancer and 100% sensitivity for stage I cancer.
• OlariscoreStrategic or Co-development Partner · 22 June 2026Commercial collaboration to support the commercialization and broad clinical access of myOLARIS-KTdx, a non-invasive urine-based laboratory developed test for surveillance of kidney graft injury in transplant recipients.
• National Cancer InstitutecoreStrategic or Co-development Partner · 31 May 2026NCI-sponsored national multicenter clinical trial for colorectal cancer patients to evaluate approaches to increase germline genetic testing among at-risk family members. Labcorp serves as exclusive genetic testing provider.
• Alliance for Clinical Trials in OncologycoreStrategic or Co-development Partner · 29 May 2026National multicenter clinical trial collaboration sponsored by the National Cancer Institute where Labcorp serves as exclusive genetic testing provider using its Invitae platform to expand cascade genetic testing among at-risk family members of colorectal cancer patients.
• Epic SystemsflagshipTechnology or Integration · 12 May 2026Expanded collaboration to integrate Labcorp's full diagnostic test menu into Epic's Aura platform, enabling clinicians to order tests and receive results directly within Epic EHR workflows. Reduces IT complexity and improves diagnostic access.
• Fox Chase Cancer Center / Temple HealthcoreStrategic or Co-development Partner · 5 May 2026Clinical trial collaboration to evaluate Labcorp Plasma Detect Genome MRD, a blood-based test that detects circulating tumor DNA to assess cancer recurrence risk in early-stage non-small cell lung cancer patients.
• SureNano ScienceminorStrategic or Co-development Partner · 24 April 2026GLP-1 agonist peptide GEP-44 GLP toxicology and pharmacology studies to be conducted in collaboration with Labcorp across rodents and non-rodent primates.
• Agilent TechnologiescoreOEM/ Whitelabel/ Licensing Partner · 22 April 2026Nationwide availability of Agilent's PD-L1 IHC 22C3 pharmDx, the only FDA-approved companion diagnostic for identifying platinum-resistant ovarian cancer patients eligible for KEYTRUDA treatment.
• PathAIcoreTechnology or Integration · 17 April 2026Expanded partnership to deploy AI-powered digital pathology platforms across Labcorp's national laboratory network, supporting digital pathology adoption and AI-assisted diagnostics.
• Amazon Web Services (AWS)coreTechnology or Integration · 14 April 2026Developed AI-powered real-world data platform in partnership with AWS and Datavant to accelerate Alzheimer's disease research by enabling faster analysis of large healthcare datasets. Platform leverages agentic AI and deidentified patient data.
• DatavantcoreTechnology or Integration · 14 April 2026AI-powered real-world data platform collaboration for connecting and analyzing deidentified healthcare data to accelerate drug development timelines.
• IlluminaflagshipStrategic or Co-development Partner · 13 April 2026Expanded collaboration to widen access to precision oncology testing, developing in vitro diagnostic and research-based tests for comprehensive genomic profiling and whole-genome sequencing. Also exploring co-commercialization of PGDx elio plasma focus Dx liquid biopsy assay.
• Children's Hospital of Philadelphia (CHOP)flagshipStrategic or Co-development Partner · 13 April 2026Strategic collaboration to accelerate the discovery, development, and nationwide availability of specialized pediatric diagnostics. Partnership combines CHOP's pediatric research expertise with Labcorp's national diagnostic infrastructure in oncology, metabolic disease, autoimmune conditions, genetics, and rare diseases.
• FujirebiocoreTechnology or Integration · 18 August 2025Labcorp's nationwide commercial launch of Fujirebio's Lumipulse G pTau217/β-amyloid 1-42 plasma ratio, the first FDA-cleared blood-based test for Alzheimer's diagnosis.
• Baystate HealthcoreStrategic or Co-development Partner · 22 April 2024Labcorp completed the acquisition of Baystate Health's outreach laboratory business and select operating assets in Massachusetts. The integration aims to enhance access to high-quality healthcare services for underserved communities and establish a regional laboratory in Holyoke, Massachusetts.
• Toxikon CorporationcoreStrategic or Co-development Partner · 19 November 2021Labcorp acquired Toxikon Corporation, a nonclinical testing services provider, to strengthen Labcorp's nonclinical development portfolio and establish a strategic presence in Boston, MA for drug development and medical device testing.
• Ovia HealthcoreStrategic or Co-development Partner · 12 August 2021Labcorp acquired Ovia Health to enhance its leadership in the women's health sector, adding digital health companion solutions for women across their health journey.
• Myriad GeneticscoreStrategic or Co-development Partner · 3 May 2021Labcorp acquired select assets from Myriad Genetics' autoimmune business, including the Vectra rheumatoid arthritis test, for $150 million in cash. The transaction aimed to strengthen Labcorp's position in rheumatology diagnostics.

Scale indicators15 records

Recent moves7 records

Expansion highlights7 records

Direct peers

• Quest Diagnostics: Quest Diagnostics is Labcorp's primary direct competitor in US clinical laboratory testing, operating a similar nationwide network of patient service centers serving physicians, hospitals, and health plans with comparable routine and esoteric test menus.
• Charles River Laboratories: Charles River competes directly with Labcorp's nonclinical development and preclinical CRO services, providing toxicology, safety assessment, and research models for biopharmaceutical clients.
• Myriad Genetics: Myriad Genetics is a molecular diagnostics company focused on hereditary cancer, pharmacogenomics, and specialty testing — overlapping with Labcorp's Invitae-based genetic testing and women's health segments. Labcorp acquired select Vectra autoimmune assets from Myriad in 2021.
• Exact Sciences: Exact Sciences competes directly with Labcorp in colorectal cancer screening (Cologuard vs. Labcorp's distribution of ColoSense) and broader oncology diagnostics, including CGP and minimal residual disease testing.

Broad incumbents

• Sonic Healthcare: Sonic Healthcare is a global medical diagnostics operator providing clinical laboratory and pathology services across multiple geographies; it competes with Labcorp's central lab and esoteric testing operations while being more diversified geographically.
• Eurofins Scientific: Eurofins is a large diversified testing services group spanning clinical diagnostics, pharma services, and food/environmental testing. It overlaps with Labcorp in clinical and bioanalytical lab services, though with a much broader industry footprint.
• IQVIA: IQVIA is a global clinical research services and real-world evidence provider that competes with Labcorp's Biopharma Laboratory Services and real-world data platform, particularly around clinical trial central lab support and pharma analytics.
• ICON plc: ICON is a global CRO offering clinical trial management and laboratory services; it competes with Labcorp in central lab services and broader drug development offerings.

Emerging players

• Natera: Natera is a specialty molecular diagnostics company focused on cell-free DNA testing in oncology, transplant surveillance (overlapping with Labcorp/Olaris myOLARIS-KTdx), and reproductive health, competing with several of Labcorp's specialty segments.
• Bio-Techne: Bio-Techne provides reagents, assays, and diagnostic tools used in life science research and clinical diagnostics, overlapping with Labcorp's esoteric testing and biomarker capabilities, particularly for research customers.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat7 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/labcorp
• YouTubeyoutube.com/c/labcorpvideo
• Facebookfacebook.com/LabCorp-1639041059681535
• LinkedInlinkedin.com/company/labcorp
• Instagraminstagram.com/labcorp/?hl=en

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Subsidiaries17 records

Funding overview

Funding rounds2 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A37 records

Investments57 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about LabCorp